HC Wainwright Comments on Alumis’ Q3 Earnings (NASDAQ:ALMS)

Alumis Inc. (NASDAQ:ALMS) – HC Wainwright issued their Q3 2027 earnings per share (EPS) estimates for shares of Alumis in a research note issued to investors on Friday, May 15th. HC Wainwright analyst M. Kapoor forecasts that the company will earn ($0.75) per share for the quarter. HC Wainwright currently has a “Neutral” rating and a $25.00 price target on the stock. The consensus estimate for Alumis’ current full-year earnings is ($2.89) per share.

Several other brokerages also recently issued reports on ALMS. Stifel Nicolaus began coverage on shares of Alumis in a research report on Wednesday, February 25th. They set a “buy” rating and a $44.00 price objective on the stock. Morgan Stanley reiterated an “overweight” rating and set a $39.00 target price on shares of Alumis in a research note on Friday. Oppenheimer raised their price target on Alumis from $50.00 to $55.00 and gave the stock an “outperform” rating in a report on Monday, March 30th. Guggenheim boosted their price target on Alumis from $32.00 to $34.00 and gave the company a “buy” rating in a research report on Friday. Finally, Chardan Capital increased their price objective on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $40.30.

Alumis Price Performance

ALMS stock opened at $21.52 on Monday. The company has a fifty day moving average price of $24.20 and a 200 day moving average price of $19.31. Alumis has a 12 month low of $2.76 and a 12 month high of $30.60. The company has a market cap of $2.74 billion, a price-to-earnings ratio of -10.87 and a beta of -0.31.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.73) by ($0.01). The firm had revenue of $1.74 million for the quarter, compared to analysts’ expectations of $2.10 million. Alumis had a negative return on equity of 88.79% and a negative net margin of 2,825.70%.

Institutional Trading of Alumis

A number of institutional investors have recently modified their holdings of the business. Samsara Biocapital LLC grew its holdings in Alumis by 19.9% during the 4th quarter. Samsara Biocapital LLC now owns 5,756,984 shares of the company’s stock valued at $56,188,000 after buying an additional 955,614 shares during the last quarter. Vanguard Group Inc. increased its position in Alumis by 18.4% during the 3rd quarter. Vanguard Group Inc. now owns 4,029,615 shares of the company’s stock worth $16,078,000 after purchasing an additional 625,404 shares in the last quarter. Cormorant Asset Management LP raised its stake in Alumis by 69.3% in the 4th quarter. Cormorant Asset Management LP now owns 3,635,596 shares of the company’s stock valued at $35,483,000 after purchasing an additional 1,488,200 shares during the last quarter. Octagon Capital Advisors LP lifted its holdings in Alumis by 11.9% in the 1st quarter. Octagon Capital Advisors LP now owns 2,830,700 shares of the company’s stock valued at $62,360,000 after purchasing an additional 300,000 shares in the last quarter. Finally, MPM Bioimpact LLC purchased a new stake in shares of Alumis during the fourth quarter worth about $23,443,000.

Trending Headlines about Alumis

Here are the key news stories impacting Alumis this week:

• Positive Sentiment: Chardan Capital raised its price target on Alumis to $40 from $38 and kept a Buy rating, signaling strong upside potential for the stock. Chardan price target raise via Benzinga
• Positive Sentiment: HC Wainwright lifted several earnings estimates for Alumis, including Q2 2026, Q3 2026, Q4 2026, FY2026, and FY2027, which suggests modestly improving expectations for the business. HC Wainwright estimate updates
• Neutral Sentiment: HC Wainwright maintained a Neutral rating with a $25 price target, which is less bullish than Chardan’s view and may temper enthusiasm. HC Wainwright coverage
• Neutral Sentiment: Recent research coverage and forecast updates appear to be the main catalyst, rather than any new operational announcement or clinical update from Alumis. Alumis consensus estimates
• Negative Sentiment: Despite the analyst support, Alumis continues to be expected to report losses across 2026 and 2027, so fundamental profitability remains a risk factor for the stock. Alumis earnings estimates

Alumis Company Profile

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.